Barry Reisberg, MD

  • Specialties: Adult Psychiatry, Geriatric Psychiatry
  • Language: English
  • Phone: 212-263-8550

About Me

Conditions and Treatments

Alzheimer's disease, memory loss, cognitive disorder, dementia, depressive disorder, bipolar disorder, memory disorders, anxiety disorder, mood disorder, psychological testing, cerebrovascular disorder
Show More Conditions

Credentials

Positions
  • Professor, Department of Psychiatry
  • Clinical Dir Aging & Dementia Rsch Ctr
  • Director of the Zachary and Elizabeth M. Fisher Alzheimer Disease Education and Research program
Board Certifications
  • American Board of Psychiatry & Neurology - Psychiatry, 1976
Education and Training
  • Residency, Metropolitan Hospital, Psychiatry, 1975
  • MD from New York Medical College, 1972
Departments

Is this your profile?

Edit profile

Is this your profile?

Edit profile

Locations and Appointments

Department of Psychiatry

145 East 32nd Street, Room 508
New York, NY 10016

Dept. of Psychiatry

560 First Avenue
New York, NY 10016

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

Research My Research

Interests

Alzheimer's disease

Research Summary

Barry Reisberg, M.D. has directed research over the past three decades which has significantly advanced current understanding and treatment of Alzheimer's disease (AD). He was the first to describe many of the most important symptoms of AD and the characteristic clinical course of the disease. His staging tools are presently governmentally mandated measures throughout the U.S., in some Canadian and European provinces, and recommended in Japan. Dr. Reisberg's work has been instrumental in the worldwide development of all three major current pharmacological treatment modalities for AD, i.e., glutamatergic antagonist treatment (memantine), treatment for behavioral disturbances in dementia (e.g., risperidone), and in the development and approval of cholinesterase inhibitor treatment (e.g., rivastigmine for mild to moderate dementia and donepezil for severe dementia). For example, Dr. Reisberg was the principal designer and Principal Investigator of the pivotal trial, published in the New England Journal of Medicine, which resulted in the US and European Union approval of the first treatment for advanced AD, memantine. Dr. Reisberg and his associates developed the concepts behind and coined the terminology, "mild cognitive impairment," a now universally recognized entity. His descriptions of an even earlier clinically manifest stage - "subjective cognitive impairment," are increasingly being recognized as the earliest manifestations of AD in seemingly normal persons. At the other end of the severity spectrum, Dr. Reisberg's staging procedures have been used in the pivotal worldwide trials of  currently approved medications for advanced AD. Dr. Reisberg's description of the retrogenic neurodevelopmental process in AD and related dementias is also advancing a new science of AD management and providing new insights into AD etiopathogenesis. Dr. Reisberg has been the recipient of numerous grants and awards for his pioneering research including a Lifetime Achievement Award for Research in Alzheimer's disease from the major worldwide organizations in the field. Dr. Reisberg is the Emeritus Director of the Clinical Core of the US National Institute on Aging (NIH) funded Alzheimer's Disease Center of the New York University School of Medicine and Clinical Director of the Aging and Dementia Research Center of the NYU School of Medicine. He serves as Professor of Psychiatry at NYU. Dr. Reisberg is also Director of the Zachary and Elizabeth M. Fisher Alzheimer's Disease Education and Resources Program at the NYU School of Medicine. Additionally, Dr. Reisberg is an Adjunct Professor at the McGill University Faculty of Medicine in Montreal, Canada.

Academic Contact

Academic office

145 East 32nd Street

Fifth Floor, Room 508

New York, NY 10016

Phone

212-263-8550

Fax

212-263-6991

Research Interests Timeline

These focus areas and their associated publications are derived from PubMed and the MeSH term library.
represents one publication
Loading...

Publications

  • Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or beta-Amyloidosis

    Wegiel, Jerzy; Flory, Michael; Kuchna, Izabela; Nowicki, Krzysztof; Yong Ma, Shuang; Wegiel, Jarek; Badmaev, Eulalia; Silverman, Wayne P; de Leon, Mony; Reisberg, Barry; Wisniewski, Thomas Wegiel, Jerzy; Flory, Michael; Kuchna, Izabela; Nowicki, Krzysztof; Yong Ma, Shuang; Wegiel, Jarek; Badmaev, Eulalia; Silverman, Wayne P; de Leon, Mony; Reisberg, Barry; Wisniewski, Thomas
    Journal of neuropathology & experimental neurology. 2017 Jun 01. 76 (6): 439-457

  • Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial

    Reisberg, Barry; Shao, Yongzhao; Golomb, James; Monteiro, Isabel; Torossian, Carol; Boksay, Istvan; Shulman, Melanie; Heller, Sloane; Zhu, Zhaoyin; Atif, Ayesha; Sidhu, Jaskirat; Vedvyas, Alok; Kenowsky, Sunnie Reisberg, Barry; Shao, Yongzhao; Golomb, James; Monteiro, Isabel; Torossian, Carol; Boksay, Istvan; Shulman, Melanie; Heller, Sloane; Zhu, Zhaoyin; Atif, Ayesha; Sidhu, Jaskirat; Vedvyas, Alok; Kenowsky, Sunnie
    Dementia geriatric & cognitive disorders. 2017 Jan 26. 43 (1-2): 100-117

  • Alzheimer's disease

    Reisberg, Barry; Franssen, Emile; Souren, Liduin EM; Kenowsky, Sunnie; Janjua, Khurram S; Veigne, Sandra W; Guillo-Benarous, Francoise; Singh, Satneet; Khizar, Asma; Shah, Umang; Shah, Romi G; Bhandal, Amandeep; Auer, Stefanie Reisberg, Barry; Franssen, Emile; Souren, Liduin EM; Kenowsky, Sunnie; Janjua, Khurram S; Veigne, Sandra W; Guillo-Benarous, Francoise; Singh, Satneet; Khizar, Asma; Shah, Umang; Shah, Romi G; Bhandal, Amandeep; Auer, Stefanie
    IN: Medical aspects of disability for the rehabilitation professionals. [New York] : Springer Publishing Company, 2017. 5th edition. p.?-?. (2558782)

Read All Publications (263)